Caris Life Sciences, Inc. (NASDAQ:CAI – Get Free Report) crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $21.68 and traded as low as $20.95. Caris Life Sciences shares last traded at $21.00, with a volume of 3,699,328 shares changing hands.
Analyst Ratings Changes
A number of equities analysts recently issued reports on CAI shares. Piper Sandler lifted their target price on Caris Life Sciences from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, November 10th. JPMorgan Chase & Co. raised their target price on shares of Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. UBS Group set a $38.00 target price on shares of Caris Life Sciences in a research report on Thursday, November 5th. BTIG Research restated a “buy” rating and issued a $38.00 price target on shares of Caris Life Sciences in a research report on Thursday, November 5th. Finally, Evercore reaffirmed an “outperform” rating and issued a $26.00 price objective on shares of Caris Life Sciences in a research note on Thursday, August 6th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Caris Life Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $31.18.
Check Out Our Latest Research Report on Caris Life Sciences
Caris Life Sciences Stock Performance
Caris Life Sciences (NASDAQ:CAI – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.02. The business had revenue of $275.36 million during the quarter. Caris Life Sciences had a net margin of 9.16% and a return on equity of 16.00%. Caris Life Sciences’s quarterly revenue was up 27.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.08 earnings per share. On average, sell-side analysts expect that Caris Life Sciences, Inc. will post 0.11 earnings per share for the current fiscal year.
Insider Buying and Selling at Caris Life Sciences
In related news, insider Brian J. Brille sold 400,000 shares of the stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the completion of the sale, the insider owned 230,303 shares in the company, valued at approximately $6,985,089.99. This trade represents a 63.46% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, President David Spetzler sold 119,212 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.76, for a total value of $2,951,689.12. Following the completion of the transaction, the president directly owned 1,182,871 shares of the company’s stock, valued at approximately $29,287,885.96. This trade represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,004,712 shares of company stock valued at $27,205,419 in the last 90 days. 50.00% of the stock is currently owned by insiders.
Institutional Trading of Caris Life Sciences
Several large investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Caris Life Sciences by 133.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock valued at $39,000 after purchasing an additional 721 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Caris Life Sciences by 839.4% in the first quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock valued at $29,000 after buying an additional 1,469 shares during the period. Fifth Third Bancorp acquired a new stake in shares of Caris Life Sciences during the first quarter worth $31,000. Root Financial Partners LLC acquired a new position in shares of Caris Life Sciences during the 3rd quarter worth about $60,000. Finally, MCF Advisors LLC acquired a new position in Caris Life Sciences during the second quarter valued at approximately $36,000.
About Caris Life Sciences
Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.
Recommended Stories
- Five stocks we like better than Caris Life Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Caris Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caris Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
